Cryoport

CYRX · NASDAQ

$17.44+$0.46 (+2.71%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $16.98

CYRX analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $19.72 (+13.1% upside)

Low: $15.15
Now: $17.44
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

CYRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Oct 13, 2026	Maintains	Buy	$25.00 → $26.00	46%
Guggenheim	Oct 1, 2026	Maintains	Buy	$16.00 → $19.00	66%
BTIG	Sep 18, 2026	Maintains	Buy	$25.00	46%
Guggenheim	Aug 7, 2026	Maintains	Buy	$12.00 → $16.00	66%
Needham	Aug 7, 2026	Maintains	Buy	$15.00 → $19.00	39%
BTIG	Jul 24, 2026	Maintains	Buy	$17.00 → $25.00	46%
Craig-Hallum	Jun 3, 2026	Maintains	Buy	$15.00 → $20.00	57%
Keybanc	May 20, 2026	Maintains	Overweight	$15.00 → $17.00	49%
Guggenheim	May 5, 2026	Maintains	Buy	$11.00 → $12.00	66%
Needham	May 5, 2026	Maintains	Buy	$13.00 → $15.00	39%

The case for and against

Updated Oct 15, 2026

Bull case

CryoPort is positioned favorably because its core Life Sciences Services business is growing faster than the broader company, with 2Q:26 revenue up 15% year over year, total revenue at $49 million, and positive adjusted EBITDA of $0.4 million for the first time since 1Q:23. The investment case is strengthened by secular demand in cell and gene therapy, where CryoPort supports 22 to 23 commercial therapies, ~779 clinical trials, and a growing mix of higher-value commercial services that can reduce earnings volatility and deepen recurring revenue. Additional upside comes from operating leverage and expanding capacity, including Paris and Santa Ana launches in Q4 2026, along with differentiated products like Fusion freezers and IntegriCell that should widen access, lift revenue per patient, and support long-term margin expansion.

Bear case

CryoPort is challenged by a business model that depends heavily on continued cell and gene therapy approvals, while its bear case explicitly assumes slower approvals, weaker revenue growth, and pressure on margins and profitability. Although Commercial Services revenue grew 27% y/y in 2Q:26, that strength was helped by roughly $1.2M of non-recurring Product revenue in 2Q:25, making comparisons tougher and highlighting uneven underlying demand, especially in MVE freezers. The company also faces execution and regulatory risk from acquisitions, third-party software and carrier dependence, complex logistics, and intense competition, all of which could disrupt operations, damage reputation, and weigh on financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.